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The epidemic of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) emerged in December
2019, and it has currently resulted in the loss of more
100,000 human lives in the US.[1] This unprecedented
SARS-CoV-2 epidemic is likely one of the largest worldwide crises in the last 100 years. SARS-CoV-2 was
originally reported to be a respiratory virus however
it seems plausible that like other coronaviruses, the
gastro- intestinal tract and the olfactory bulb are ports
of entry for SARS-CoV-2. In fact, smelling abnormalities have been the clinical presentation in some cases
with coronavirus disease 2019 (COVID-19).[2] Furthermore, CNS symptoms have been reported in about one
third of patients with COVID-19 [3] and SARS-CoV2 have been isolated from CSF in patients with CNS
symptoms.[4, 5]

A patient with neurologic symptoms at the
time of the COVID-19 epidemic
Patross et al. reported a male patient with 2 days of
confusion, headache, and fever with the final diagnosis of presumptive meningitis.[6] Blood cultures grew
S. pneumoniae. Subsequently, the throat swab COVID19 PCR test was reported positive. Interestingly, the patient did not have respiratory or gastrointestinal symptoms. The patient improved clinically on appropriate antibiotic treatment and was discharged home to
continue the treatment. It was not clear whether this
patient had olfactory or gustatory abnormalities, as
these are difficult to evaluate in a confused patient.
The MRI showed findings that were highly suggestive for ventriculitis supporting the diagnosis of acute
brain injury and very likely meningitis. This case is
unique to explore the association of SARS-CoV-2 and
CNS infections and the tropism of SARS-CoV-2 to CNS.
Furthermore, SARS-CoV-2 might facilitate the invasion
of other pathogens into the CNS. Because the cerebrospinal fluid exam was not done in this patient, the
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etiology of the CNS symptoms was not confirmed. The
etiologies of the CNS symptoms could be due to either SARS-CoV-2 or S. pneumoniae, both pathogens or
metabolic abnormalities. The lack of CSF exam in a patient with presumptive meningitis during the time of
COVID-19 is a diagnostic limitation. This practice of
not doing a CSF exam is acceptable if the risk of infection for the physician is substantial. An additional
observation is that the fact that this patient with fever
and CNS complaints did not receive a SARS-CoV-2 test
upon initial presentation. This illustrates the suboptimal awareness of SARS-CoV-2 causing CNS infection.

Characterization of the neurological findings in patients with COVID-19
CNS symptoms have been reported in 36.4% of 214
patients with COVID-19.[3] When comparing patients
with severe COVID-19 versus those without severe
COVID-19, the impaired consciousness was reported
in 14.8% vs. 2.4% and cerebrovascular accidents in 5.7%
vs. 0.8% respectively.[3] Interestingly, fever, cough, sore
throat and diarrhea were less common among patients
without severe illness.[3] Oxley et al. reported largevessel strokes as a presenting feature of COVID-19 in
patients with ages 33 and 49 years with no or mild
comorbidities.[7] In addition, neurological signs were
found in 84% from a series of 58 patients with severe
SARS-CoV-2.[8] In this series, fever was present in only
16% of patients. However, corticospinal tract signs
were present in 76% of the patients.
The brain MRI revealed leptomeningeal enhancement
in 62%, perfusion abnormalities in 100% and ischemic
CVA in 23% of the patients. However, the SARS-CoV-2
PCR was negative in the cerebrospinal fluid in 7 out of 7
patients. Overall, patients with neurological symptoms
were more severely ill but reported fever, respiratory
and gastrointestinal symptoms less often.
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Pathogenesis of CNS symptoms in patients with COVID-19
The findings of more neurological symptoms among
patients with severe COVID-19 could be due to the
inflammatory and thrombotic complications. There
appear to be a correlation among the severity of the
COVID-19, increasing findings of neurological symptoms, high levels of C-reactive protein (CRP) and Ddimer.[9, 10] CRP was 3.94-fold times and D-dimer
2.25-fold times higher in patients with severe COVID19 than those with non-severe COVID-19. High CRP
levels is triggered by IL-6 that may reflect the ongoing cytokine release syndrome (CRS) leading to organ injury including neurological symptoms. The angiotensin converting enzyme-2 (ACE-2) is found in
many cells and organs including the CNS. ACE converts angiotensin-I into angiotensin-II; which through
the angiotensin type-1 receptor (AT-1R) triggers vasoconstriction, inflammation, thrombosis and activation
of microgial cells plus neuroinflammation.[11] On the
other hand, ACE-2 converts angiotensin II into angiotensin 1-7 which binds to angiotensin type 2 receptor (AT-2R) triggering vasodilation and less thrombosis. Thus, ACE-2 is a master regulator of the reninangiotensin system (RAS) by converting angiotensin I
and angiotensin II to 1-9 and 1-7 respectively. ACE-2 is
the receptor of SARS-CoV-2. Upon the virus binding to
the ACE-2, the counter regulation activity of the ACE-2
over RAS is lost.
The olfactory bulb is a potential port of entry for SARSCoV-2 and S. pneumoniae for the case under discussion
with presumptive meningitis. The fact this patient did
not have respiratory symptoms and the chest CT did
not show lung abnormalities makes it tempting to consider the possibility that the olfactory bulb as the port of
entry for both pathogens. Nasal epithelial cells display
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the highest expression of the SARS-CoV-2 receptor, the
ACE-2, in the respiratory tract.[12] Furthermore, the
olfactory bulb has been reported to be the port of entry for bacteria, fungi and protozoa. In 1937, Rake G.
showed that pneumococci instilled intranasally in mice
pass through the mucosal surfaces to the peripheral
blood within 2 minutes.[13] A test with Prussian blue
showed that pigment went through the olfactory cells,
lymphatics and blood vessels, perineural sheaths and
then to the subarachnoid space and pia mater over the
olfactory bulb. These findings were confirmed by others, such as Ginkel et al.[14]

Conclusion
The case reported by Patross et al. with neurological
symptoms and MRI findings consistent with CNS injury could be due to S. pneumococcus and SARS-CoV2 infection.[6] Regardless of the lack of confirmation
of the etiology of this case, it illustrates very well the
challenges to deliver optimal care of patients at the
time of COVID-19 epidemic. Physicians are concerned
about their own safety in doing a lumbar puncture in
a patient with presumptive COVID-19. This practice
of not doing a CSF exam on a patient in the time of
COVID-19 deserves a good analysis. It is very important that physician protects his/her own health. Secondly, physicians are not expected to spread the infection. Finally, the fact that this patient with fever
and CNS complaints did not receive a SARS-CoV-2 test
upon initial presentation illustrate well the suboptimal awareness of SARS-CoV-2 causing CNS infection.
More studies are needed to evaluate the mechanisms
causing CNS symptoms in patients with COVID-19 including in those with S. pneumoniae bacteremia. New
guidelines should include SARS-CoV-2 tests in patients
with neurological symptoms and fever.
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